Status:
RECRUITING
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
Lead Sponsor:
University of Miami
Collaborating Sponsors:
Phathom Pharmaceuticals
NRG Oncology
Conditions:
H. Pylori Infection
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment fo...
Eligibility Criteria
Inclusion
- Participants in Aim 1 that received a positive result for H. Pylori (HP) testing
- Participants are advised to only begin re-testing procedures in Aim 2 if they have finished the medication regimen for HP treatment at least 6 weeks ago
Exclusion
- Pregnant women, those who are breastfeeding, or those who are planning to become pregnant/breastfeed
Key Trial Info
Start Date :
November 6 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 6 2027
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT07224048
Start Date
November 6 2024
End Date
November 6 2027
Last Update
November 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136